Cardiovascular Today—March 26, 2026

This week’s Cardiovascular update highlights regulatory approvals, device innovation, AI-enabled care advancements, and emerging clinical and observational data across heart disease and transplant care.

In Today’s Newsletter

Dive deeper

🫀 Wolters Kluwer expands AHA journal publishing [1] [19 Mar 2026]

https://www.wolterskluwer.com/en/news/wolters-kluwer-expands-access-to-american-heart-associations-leading-cardiovascular-research
Context: Wolters Kluwer has published American Heart Association journals since 1988.
Key point: Wolters Kluwer expanded its publishing relationship with the American Heart Association to include Stroke: Vascular and Interventional Neurology, for a total of 12 titles.
Implication: May broaden access to peer-reviewed cardiovascular and brain health research across subscription and open-access channels.

⌚ Smartwatch signals heart failure worsening risk [2] [Canada • 20 Mar 2026]

https://www.newswire.ca/news-releases/smartwatches-show-promise-in-identifying-increased-risk-of-heart-failure-hospitalization-856021330.html
Context: Observational study, 217 people with heart failure, 3 months, Apple Watch-based monitoring, plus independent US validation cohort.
Key point: University Health Network researchers reported that smartwatch-derived declines in daily cardiopulmonary fitness were associated with higher risk of hospitalization or urgent treatment.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

⚡ Medtronic OmniaSecure gains FDA approval for CSP use [3] [US • 23 Mar 2026]

https://www.prnewswire.com/news-releases/medtronic-omniasecure-defibrillation-lead-is-the-first-lead-of-its-kind-to-receive-fda-approval-for-conduction-system-pacing-302720215.html
Context: FDA expanded the indication for OmniaSecure defibrillation lead to left bundle branch area placement, supported by LEADR LBBAP data.
Key point: Medtronic said OmniaSecure is the first FDA-approved defibrillation lead for placement in the left bundle branch area for conduction system pacing.
Implication: May influence prescriber choice and payer reviews pending full data.

🤖 Cleveland Clinic, DASI Simulations partner on AI-enabled TAVR planning [4] [US • 24 Mar 2026]

https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/tavr/cleveland-clinic-partners-ai-company-develop-tavr-software
Context: Phase one validates PrecisionTAVI alongside routine care, phase two focuses on co-development of an updated version.
Key point: Cleveland Clinic and DASI Simulations launched a partnership around AI-supported TAVR planning and future procedure execution workflows.
Implication: Signals pipeline investment and modality expansion.

🧫 Posaconazole outperformed itraconazole after heart transplant [5] [23 Mar 2026]

https://www.infectiousdiseaseadvisor.com/news/posaconazole-itraconazole-fungal-prophylaxis-heart-transplant/
Context: Retrospective cohort study in heart transplant recipients, nonrandomized design, 1-year follow-up.
Key point: Posaconazole prophylaxis was associated with fewer fungal infections, higher therapeutic drug-level attainment, and less switching to alternative therapy than itraconazole.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

❤️ JenaValve Trilogy approved for severe aortic regurgitation [6] [US • 23 Mar 2026]

https://www.tctmd.com/news/fda-approves-jenavalves-trilogy-aortic-regurgitation
Context: FDA approval was based on ALIGN-AR in high-surgical-risk patients with symptomatic severe aortic regurgitation.
Key point: JenaValve’s Trilogy became the first FDA-approved dedicated transcatheter heart valve for this patient population.
Implication: May influence prescriber choice and payer reviews pending full data.

🫀 Corcym reports first US use of Perceval Plus Lancelot [7] [US • 20 Mar 2026]

https://cardiovascularnews.com/first-patient-treated-in-usa-with-next-generation-sutureless-aortic-valve/
Context: Company said the procedure was performed in September 2025 and the patient recovered and returned to everyday activities.
Key point: Corcym announced the first US patient treated with its next-generation Perceval Plus Lancelot sutureless aortic valve.
Implication: May influence prescriber choice and payer reviews pending full data.

📱 Clarius launches AI-guided cardiac ultrasound training tool [8] [23 Mar 2026]

https://appliedradiology.com/articles/clarius-introduces-ai-driven-t-mode-heart-for-cardiac-ultrasound-training
Context: T-Mode Heart adds real-time AI labeling and split-screen anatomical guidance for handheld ultrasound users.
Key point: Clarius introduced T-Mode Heart to support cardiac ultrasound training for primary care, emergency clinicians, and medical students.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Cardiovascular AI is moving from image review into workflow support, seen in smartwatch monitoring [2], TAVR planning [4], and ultrasound training [8].
Device innovation remains active across rhythm management and structural heart, with Medtronic OmniaSecure [3], JenaValve Trilogy [6], and Corcym Perceval Plus Lancelot [7].
Heart failure and transplant care continue to add digital and pharmacologic monitoring options, though some evidence remains observational or retrospective [2][5].
Publishing and dissemination infrastructure also matters, with Wolters Kluwer and the American Heart Association expanding reach for cardiovascular research [1].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What changed in the Wolters Kluwer and American Heart Association relationship?

Wolters Kluwer said it expanded its publishing agreement with the American Heart Association to include Stroke: Vascular and Interventional Neurology, bringing the total to 12 AHA journal titles [1]. This is a publishing and access update, not a clinical trial result.

What did the smartwatch heart failure study actually show?

In a 3-month observational study, smartwatch-derived declines in daily cardiopulmonary fitness were associated with higher risk of unplanned care in people with heart failure [2]. The report also described an external validation cohort, but this was not a randomized intervention study [2].

Why is Medtronic OmniaSecure notable?

Medtronic said OmniaSecure is the first FDA-approved defibrillation lead for placement in the left bundle branch area for conduction system pacing [3]. The approval expands pacing options for patients who need both defibrillation and pacing support [3].

What is Cleveland Clinic validating with DASI Simulations?

The partnership centers on PrecisionTAVI, an FDA-approved planning tool that simulates valve deployment scenarios using patient data and imaging [4]. Cleveland Clinic is first validating it in parallel with routine care, then plans co-development work [4].

Why does JenaValve Trilogy matter in aortic regurgitation?

The FDA approval makes Trilogy the first dedicated transcatheter heart valve approved in the US for symptomatic severe aortic regurgitation in high-surgical-risk patients [6]. The source says this approval was based on ALIGN-AR [6].

How strong is the posaconazole versus itraconazole evidence after heart transplant?

The study was retrospective and nonrandomized, so design limits apply [5]. Still, the reported findings favored posaconazole for therapeutic level attainment and 1-year infection outcomes in this cohort [5].

Entities / Keywords

Cardiovascular, American Heart Association, Wolters Kluwer, Circulation, Stroke, Stroke: Vascular and Interventional Neurology, heart failure, smartwatch monitoring, wearable monitoring, University Health Network, Peter Munk Cardiac Centre, Transform HF, Medtronic, OmniaSecure, conduction system pacing, CSP, left bundle branch area pacing, LBBAP, LOT-CRT, LEADR LBBAP, Cleveland Clinic, DASI Simulations, PrecisionTAVI, TAVR, structural heart, posaconazole, itraconazole, heart transplant, invasive fungal infection, JenaValve, Trilogy, aortic regurgitation, ALIGN-AR, Corcym, Perceval Plus Lancelot, sutureless aortic valve, Clarius, T-Mode Heart, handheld ultrasound, point-of-care ultrasound, POCUS